Research programme: diabetes and obesity therapeutics - Genfit

Drug Profile

Research programme: diabetes and obesity therapeutics - Genfit

Alternative Names: G 220; MKG 02; TGFTX 2

Latest Information Update: 30 Mar 2009

Price : $50

At a glance

  • Originator Genfit; Merck Sante
  • Developer Genfit
  • Class
  • Mechanism of Action Cytoplasmic and nuclear receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 24 Mar 2009 Genfit acquires a research programme (MKG 02) on type 2 diabetes and obesity from Merck Sante
  • 24 Mar 2009 Preclinical trials in Obesity in France (unspecified route)
  • 12 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top